| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_afb3087981365315fce608ca78c711d3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2410-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-352
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2121-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2871
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2835
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2821
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-28 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-352
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56966
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-185
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-487 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 |
| filingDate |
2018-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d6e5487f49d6649f6d64772b2b0f8ef |
| publicationDate |
2019-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2019045575-A1 |
| titleOfInvention |
IMPROVEMENTS IN IGF-1 ANALYSIS, ADJUSTMENT AND DISEASE MANAGEMENT IN NON-NEUROLOGICAL AND / OR NEUROLOGICAL STATES |
| abstract |
The present invention relates to improvements relating to IGF1 analysis, adjustment and disease management of non-neurological and / or neurological conditions. More specifically, the invention relates to methods relating to the clinical application of the cyclic glycine-proline biomarker (cGP) for the prediction of risk and recovery of non-neurological and / or neurological conditions with IGF dysfunction. -1 and the use of a cGP-containing organic or plant-based material such as a blackcurrant anthocyanin concentrate (BCA) extract for the treatment thereof. The methods more precisely measure IGF-1 function in vivo indirectly using cGP and the ratio and cGP / IGF-1, together with means for adjusting the cGP and cGP / IGF-1 ratio (and thus the active concentration of IGF-1), and specific treatment methods for individuals with a lower cGP level or reduction from a standard set of baseline data. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023113623-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020196686-A |
| priorityDate |
2017-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |